Pharmaceutical companies are being squeezed by declining R&D productivity, and at the same time, more and more generic competition. Consequently many are seeking to focus their pipelines. One way to do this is divest assets in non-core programs. However, typical business development outlicensing can take some time for each compound, series, or program. This would… Read More Process to Divest Therapeutic Pipelines